Stock AnalizVir Biotechnology, Inc. VIR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2019 · data as of November 13, 2026
Vir Biotechnology, Inc. (VIR) is a healthcare company listed in the US with a market value of about $1.7B. In the twelve months to September 30, 2026 it had revenue of $303M and net income of -$185M, a net margin of -61.0%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -16%.
Score: 0.8 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $303M | $69M | $74M | $86M | $1.6B | $1.1B | $76M | $8M | $11M | $3M |
| Net income | -$185M | -$438M | -$522M | -$615M | $516M | $529M | -$299M | -$175M | -$116M | -$70M |
| Free cash flow | -$142M | -$397M | -$454M | -$800M | $1.6B | -$69M | -$197M | -$139M | -$102M | -$69M |
| EPS (diluted) | $-1.25 | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 | $-2.51 | $-5.76 | $-15.12 | $-32.45 |
| Net margin | -61.0% | -638.9% | -703.4% | -713.7% | 31.9% | 48.2% | -391.1% | -2159.0% | -1086.3% | -2579.5% |
| ROIC | — | -43.9% | -46.9% | -39.1% | 25.8% | 25.8% | -29.8% | -33.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $23.38, 135% above the current price; targets range from $17.00 to $30.00; the consensus rating is “Strong buy”; expected EPS is $-0.99 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Vir Biotechnology pay a dividend?
Not currently.
Is Vir Biotechnology a good stock to buy?
We do not give buy or sell advice. Vir Biotechnology scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.